President Donald Trump is reportedly planning to issue an executive order as soon as this week signaling the administration’s willingness to explore the therapeutic benefits and safety of the psychedelic substance ibogaine.
CBS News reported on Thursday that while the administration doesn’t plan to reschedule the psychedelic out of Schedule I of the Controlled Substances Act (CSA) at this time, the move is “meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.”
The outlet said that while officials are still in the process of drafting the executive order’s provisions, the aim is to help determine whether ibogaine is what one source described as “snake oil” or is instead a legitimate treatment.
Citing two sources, CBS reported that the president’s move could come within days.
Early research and experience indicates that ibogaine can help people suffering with post-traumatic stress disorder, traumatic brain injuries and drug addiction.
Lawmakers in a number of states have passed legislation to support clinical trials with the aim of developing ibogaine into a legal medication with approval from the Food and Drug Administration (FDA).
Texas officials, for example, recently announced that the state
Read full article on Marijuana Moment
